OncoSil Medical Limited (ASX:OSL)

OncoSil Medical Financials Overview

Financials in millions AUD. Fiscal year is July - June.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Revenue Revenue Growth	5.23	5.23	1.54	1.57	1.47	1.06
Revenue Growth	40.37%	240.57%	-1.92%	6.68%	38.00%	-18.09%
Gross Profit Gross Profit Growth	2.87	2.87	-0.72	0.06	-0.12	0.09
Operating Income Operating Income Growth	-10.87	-10.87	-15.09	-11.98	-11.34	-10.58
Net Income Net Income Growth	-10.86	-10.86	-15.1	-11.91	-11.34	-10.73
Earnings Per Share EPS Growth	-0.48	-0.48	-1.38	-2.16	-4.02	-5.29
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023
Australia Australia Growth	0.02	0.02	0.06	-
Europe Europe Growth	1.16	0.87	0.46	0.11
Middle East Middle East Growth	-	0.29	-	-
Total Total Growth	1.49	1.17	0.52	0.37

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Cash & Investments Cash & Investments Growth	6.48	6.48	5.11	4.5	9.39	11.28
Total Debt Total Debt Growth	0.01	0.01	0.07	0.07	0.17	0.3
Net Cash (Debt) Net Cash Growth	6.46	6.46	5.04	4.43	9.22	10.98
Net Cash Growth	129.76%	28.20%	13.75%	-51.96%	-15.97%	-6.63%
Net Cash Per Share Net Cash Per Share Growth	0.29	0.29	0.46	0.80	3.27	5.41

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Operating Cash Flow Operating Cash Flow Growth	-10.47	-10.47	-12.06	-10.82	-11.32	-10.11
Capital Expenditures CapEx Growth	-0	-0	-0.01	-0.2	-0.06	-0.01
Free Cash Flow Free Cash Flow Growth	-10.47	-10.47	-12.08	-11.02	-11.37	-10.12
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Gross Margin	54.92%	54.92%	-46.79%	3.55%	-8.27%	8.55%
Operating Margin	-207.96%	-207.96%	-982.80%	-765.58%	-772.48%	-994.72%
Pretax Margin	-207.70%	-207.70%	-983.53%	-761.07%	-772.98%	-1008.73%
Profit Margin	-207.70%	-207.70%	-983.53%	-761.07%	-772.98%	-1008.73%
FCF Margin	-200.32%	-200.32%	-786.66%	-704.07%	-775.06%	-951.30%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 28, 2026	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Forward PE	-	6.53	6.53	6.53	6.53	6.53
PS Ratio	6.94	4.19	11.12	8.51	16.16	37.28

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 28, 2026

Data Sources Report a data error